Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial

BACKGROUND: Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) by using dexamethasone combined with palonosetron for patients who received moderate-emetogenic chemotherapy (MEC), some of these patients still suffer from CINV. We evaluated whether aprepi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yi, Wu, Zehua, Shi, Lishuo, Shen, Cailu, Zhang, Jianwei, Hu, Huabin, Li, Weiwei, Cai, Yue, Xie, Xiaoyu, Ling, Jiayu, Zheng, Qin, Deng, Yanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167865/
https://www.ncbi.nlm.nih.gov/pubmed/35747189
http://dx.doi.org/10.1016/j.eclinm.2022.101480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167865/
https://www.ncbi.nlm.nih.gov/pubmed/35747189
http://dx.doi.org/10.1016/j.eclinm.2022.101480

Ejemplares similares